Professor Shi Jun highlighted how aplastic anemia (AA) is moving from traditional, one‑size‑fits‑all care to precision, diversified treatment. Recent real‑world data show that patients who undergo hematopoietic stem‑cell transplantation often lose muscle mass (sarcopenia) in the first year, and those with persistent loss at six months have worse outcomes. Immune‑checkpoint inhibitors can trigger AA, but the risk is low—under 0.5% in large electronic‑health‑record studies. Adding the thrombopoietin‑receptor agonist eltrombopag to standard immunosuppressive therapy (IST) improves response rates without raising toxicity, though the benefit is modest compared to controlled trials. An expert consensus now offers practical guidance on using these agents. A Chinese multicenter study confirmed that eltrombopag combined with intensive IST boosts survival in adults and narrows the gap with pediatric outcomes. Meanwhile, a novel traditional‑Chinese‑medicine formula (Modified Gui‑Lu‑Er‑Xian‑Jiao) was shown to enhance T‑reg cell function via IL‑2/STAT5 and miR‑17‑5p/Eos pathways, further supporting IST efficacy. The most exciting breakthrough is the emergence of CD38 monoclonal antibodies, which have achieved roughly 40% remission in refractory cases and may soon become a standard option. Together, these advances promise higher remission rates, lower costs, and fewer side‑effects, bringing AA patients closer to longer, better lives.
Read moreAt the 2026 China Hematology Conference, Professor Shi Jun shared the latest advances that could change the outlook for patients with aplastic anemia (AA). First, researchers have confirmed that muscle loss (sarcopenia) after stem‑cell transplants is common and predicts poorer recovery, especially when muscle mass continues to drop six months post‑transplant. A large electronic‑health‑record study also showed that AA triggered by immune‑checkpoint cancer drugs is very rare—occurring in less than 0.5% of patients. Adding the drug eltrombopag to standard immunosuppressive therapy improves response rates in adults, bringing outcomes closer to those seen in children, while keeping side‑effects similar to traditional treatment. An expert consensus now offers clear guidance on using thrombopoietin‑receptor agonists, helping doctors apply these medicines more consistently. A Chinese multicenter trial confirmed that intensive immunosuppression plus eltrombopag boosts survival and narrows the gap between adult and pediatric results. Meanwhile, a novel traditional‑Chinese‑medicine formula (Modified Gui Lu Er Xian Jiao) was found to enhance immune regulation and reduce cell death, further strengthening standard therapy. Perhaps the most exciting development is the discovery of CD38 monoclonal antibodies as a potential new drug class; early trials show about 40% effectiveness in patients who cannot receive a stem‑cell transplant. Together, these findings promise safer, more effective, and more affordable options for people living with aplastic anemia.
Read more